Print Preview Area

Gilead Sciences Refiles New Drug Application with the FDA for Single-Tablet Regimen of Truvada and TMC278
Gilead, 02/11/2011

Gilead Sciences, Inc. announced that it has refiled a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the single–tablet regimen of Truvada(emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non–nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV–1 infection in adults.

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Pharma News Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

Gilead Sciences Refiles New Drug Application with the FDA for Single-Tablet Regimen of Truvada and TMC278 Gilead, 02/11/2011

Gilead Sciences Refiles New Drug Application with the FDA for Single-Tablet Regimen of Truvada and TMC278
Gilead, 02/11/2011